Filing Flows › Mirum Pharmaceuticals (MIRM) › R&D spending
Mirum Pharmaceuticals (MIRM) R&D spending by quarter
Mirum Pharmaceuticals' R&D spending was $108M in Q3 2026 (third quarter 2026), +19% from Q2 2026. Over the last 7 quarters it ranged from $43.0M (Q3 2025) to $108M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $108M | +19% | +151% |
| Q2 2026 | $90.5M | -8% | +97% |
| Q1 2026 | $97.9M | +92% | +113% |
| Q4 2025 | $51.1M | +19% | — |
| Q3 2025 | $43.0M | -7% | — |
| Q2 2025 | $46.1M | 0% | — |
| Q1 2025 | $46.0M | — | — |
Q3 2026 at a glance
Mirum Pharmaceuticals, Q3 2026: revenue $186M (+40% year over year), operating margin -32.2%, net loss $40.8M, operating cash flow −$4.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Mirum Pharmaceuticals' R&D spending?
Mirum Pharmaceuticals' R&D spending was $108M in Q3 2026 (third quarter 2026), +19% from Q2 2026.
How has Mirum Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $43.0M (Q3 2025) to $108M (Q3 2026).